Sepracor introduces Alvesco inhalation aerosol in US

Alvesco HFA is a new inhaled corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. This asthma treatment is available in 80mcg/actuation and 160mcg/actuation dosage strengths.

Adrian Adams, president and CEO of Sepracor, said: “Our respiratory sales specialists, as well as our recently deployed, Sepracor-managed contract sales force, have begun to introduce the product to allergists and pulmonologists, and we anticipate expanding our reach to primary care physicians and other specialists in the coming months.”